A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China

• Published in: Zhongguo fei ai za zhi Vol. 15; no. 6; pp. 332 - 339
• Main Authors: Li, Longyun, Zhong, Wei, Liao, Meilin, Chen, Li, Han, Baohui, Guan, Zhongzhen, Yu, Shiying, Liu, Xuyi, Wu, Yilong, Jiang, Guoliang, Xu, Jianming, Chen, Jia, Tao, Min, Luo, Rongcheng, Li, Weimin, Xu, Nong, Zhao, Xiao, Wang, Mengzhao
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 01-06-2012; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Cancer therapies; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Chemotherapy; China; Cross-Sectional Studies; Epidermal growth factor; Expand Access Program (EAP); Female; Gefitinib; Genotype; Hospitals; Humans; Long-term survival; Lung cancer; Lung neoplasms; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Medical prognosis; Middle Aged; Mutation; Oncology; Prognosis; Public Health Practice - statistics & numerical data; Quality of Life; Quinazolines - adverse effects; Quinazolines - therapeutic use; Respiratory diseases; Retrospective Studies; Safety; Survivors - statistics & numerical data; Time Factors; Treatment Outcome; China; Beijing China
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2012.06.03

The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer (NSCLC) patients who failed to respond to standard treatment or who could not tolerate chemotherapy. The primary objective was to describe the quality of life (QoL), tumor control status, drug safety, and clinical/genomic features of active long-term survivors enrolled in the EAP. The secondary objective was to determine the clinical characteristics of long-term survivors in the EAP program.
In this descriptive observational study, data were collected based on epidemiological research methods. The data of patients who were actively participating in the EAP and still undergoing gefitinib treatment were collected in a cross-sectional manner to reflect the current status of each patient. Meanwhile, the data of patients who had been on gefitinib treatment for more than three years and had already been terminated from the EAP or those who were fast progressors were collected retrospectively.
A total of 934 patients were screened in the EAP database. Among these patients, 25 were active long-term survivors still enrolled in the EAP and 34 were long-term survivors who had been terminated from the program. These 59 patients were enrolled in 15 different centers in China, and the remaining 875 patients were fast progressors. The median scores for the Functional Assessment of Cancer Therapy-Lung (FACT-L), Trial Outcome Index (TOI), and Lung Cancer Subscale (LCS) of the 25 long-term survivors were 64.5, 37 and 12.5, respectively. The performance status 0-1 accounted for 91.6% of the data observed during the cross-sectional survey. For active long-term survivors, the objective response rate was 37.5%, the disease control rate was 87.5%, and the median duration of response time was almost 68 months. In the long-term survivor group, no serious and new adverse events were reported. Patients who were aged under 65 years (68.5%), affected with adenocarcinoma (81.4%), female (55.9%), or had never smoked (71%) accounted for majority of the long-term survivors. The percentage of females was significantly higher in the long-term survivor group than in the fast progressor group (P=0.02). Three tissue samples were collected from each of the 24 active long-term survivors, and one patient was found to be positive of EGFR mutation. Twenty-two blood samples were also collected, and one patient tested positive for EGFR mutation. The Ki67 protein expression was also tested in three tissue samples, and two of these were found positive for Ki67 protein expression, with a response duration time of over 73 months.
A 250 mg dose of gefitinib offers good QoL and is safe for advanced NSCLC long-term survivors even after more than three years of treatment. According to the evaluation of the current tumor control statuses of patients, gefitinib demonstrates good efficacy in these active long-term survivors.